What does Bio-Rad Laboratories do?
Bio-Rad Laboratories, Inc. is a global supplier of instruments, systems, reagents, consumables, software, and laboratory quality-control products. Its Class A shares trade on the New York Stock Exchange under BIO, while Class B shares trade under BIO.B. The company is not a drug developer; it sells the tools that researchers, biopharmaceutical manufacturers, hospitals, blood banks, and diagnostic laboratories use to study biology, produce therapies, and generate reliable test results.
The company reports two operating segments. Life Science serves research, bioprocessing, food testing, and education. Clinical Diagnostics supplies test systems, specialized quality controls, informatics, blood-typing products, diabetes and hemoglobin testing, autoimmune and infectious-disease solutions, and other in-vitro diagnostic applications. Bio-Rad describes itself on its official company overview as a partner to researchers and clinicians, with annual sales of about $2.6 billion in 2025 and operations across more than 30 countries.
Why does this portfolio matter?
Bio-Rad sits at an important junction between scientific discovery and routine healthcare. A university laboratory may use its PCR, electrophoresis, chromatography, imaging, antibody, or cell-analysis tools. A biopharmaceutical customer may use process chromatography media and digital PCR in development or manufacturing. A hospital laboratory may use Bio-Rad instruments and reagents for blood typing, diabetes monitoring, autoimmune testing, or quality assurance. That breadth reduces dependence on one disease area, but it also makes execution demanding because the company must manage thousands of products, regulated workflows, global manufacturing, and regional reimbursement systems.
How does Bio-Rad make money, and which segment matters most?
Bio-Rad earns revenue from the sale of instruments and systems, but the stronger economic feature is the continuing demand for reagents, test kits, controls, cartridges, and consumables after an instrument is installed. Clinical laboratories generally validate and standardize workflows around specific platforms. Changing a platform can require method verification, staff retraining, new quality procedures, and regulatory documentation. This creates switching costs and makes the installed base a recurring-revenue engine.
Which segment has the stronger recurring-revenue profile?
| Segment | FY2025 sales | FY2025 segment gross profit | Economic logic |
|---|---|---|---|
| Clinical Diagnostics | $1,562.1M | $786.8M | Installed instruments pull through recurring reagents, test kits, controls, and service. |
| Life Science | $1,021.1M | $553.1M | A broad research portfolio combines instrument cycles with consumables and application-specific assays. |
| Consolidated | $2,583.2M | $1,339.9M | Diversification across research and routine diagnostics, with 60% of FY2025 sales outside the U.S. |
The segment table comes from Bio-Rad’s 2025 Form 10-K. Clinical Diagnostics was larger, while Life Science had a somewhat higher reported segment gross-margin percentage in 2025. The mix is strategically useful: diagnostics can provide steadier consumables demand, while life science offers exposure to high-value technologies such as droplet digital PCR, cell analysis, chromatography, and bioprocessing.
Why are installed instruments, consumables, and quality systems central to Bio-Rad’s model?
The business model is best understood as a workflow ecosystem rather than a catalog of unrelated products. Bio-Rad places or sells an instrument, supports validation and training, and then supplies the reagents, controls, software, and service required to keep the workflow productive. In the first quarter of 2026, lease elements in reagent-rental arrangements represented about 3% of total revenue, but the broader pull-through effect is more important than the lease percentage alone.
Where is Bio-Rad especially differentiated?
Bio-Rad’s strongest positions are in specialized niches where analytical performance, reference quality, and workflow reliability matter more than headline scale. The company’s official product portfolio spans droplet digital PCR, real-time PCR, electrophoresis, imaging, antibodies, chromatography, flow cytometry, and related research applications. Its clinical portfolio includes independent quality controls, blood typing, hemoglobin testing, autoimmune testing, and infectious-disease applications.
Clinical quality controls are a particularly attractive example. Laboratories use independent controls to verify that instruments and assays are producing reliable results. The value proposition is not simply the price of a control vial; it is confidence in patient testing, accreditation support, and operational consistency. Bio-Rad’s clinical diagnostics portfolio highlights controls compatible with multiple major testing platforms, broadening the addressable installed base beyond Bio-Rad instruments alone.
What did Bio-Rad’s latest quarter show?
The quarter ended March 31, 2026 showed a contrast between reported growth and underlying demand. Revenue rose 1.1% to $592.1 million, helped by foreign exchange, while currency-neutral sales declined 4.2%. Life Science remained essentially flat on a reported basis but fell 4.3% currency-neutral, reflecting continued pressure in academic research, particularly in the Americas. Clinical Diagnostics rose 1.9% reported but declined 4.1% currency-neutral, mainly because regional conflict disrupted demand and logistics in parts of EMEA.
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Net sales | $592.1M | $585.4M | Reported growth was positive, but currency-neutral sales declined 4.2%. |
| Gross margin | 52.3% | 52.3% | Stable despite higher material and logistics costs in Life Science. |
| Operating income | $34.1M | $23.7M | Operating margin improved to about 5.8% from about 4.0%. |
| R&D expense | $62.9M | $73.5M | Lower restructuring costs reduced R&D expense to 10.6% of sales. |
| Net income (loss) | $(527.1)M | $64.0M | The loss was dominated by a $727.7M holding loss on Sartorius shares. |
| Operating cash flow | $108.1M | $129.9M | Lower customer receipts and higher payments reduced cash generation. |
Why is GAAP net income unusually noisy?
Bio-Rad’s stake in Sartorius AG is recorded at fair value, so changes in Sartorius’s share price flow through Bio-Rad’s income statement. In Q1 2026, Bio-Rad recorded a $738.2 million loss from changes in equity securities and a loan receivable, including a $727.7 million holding loss on Sartorius. That accounting effect overwhelmed $34.1 million of operating income. Researchers should therefore separate operating performance from investment revaluation. Bio-Rad’s Q1 2026 Form 10-Q and first-quarter earnings release also show that management reduced its full-year 2026 currency-neutral revenue outlook to a range of a 3.0% decline to 0.5% growth and lowered expected non-GAAP operating margin to 10.0%-12.0%.
Which strategic turning points shaped Bio-Rad’s current portfolio?
Bio-Rad’s history explains why the company combines mature diagnostic franchises with research technologies such as digital PCR. The relevant story is not a list of old launches; it is a sequence of platform decisions that created today’s installed base, technical know-how, and product breadth.
-
1952David and Alice Schwartz founded Bio-Rad around ion-exchange materials, establishing the separation-science foundation that still supports chromatography and protein-analysis products.
-
1967The company entered clinical diagnostics with a commercial thyroid-hormone test, beginning the diversification from research tools into regulated patient-testing workflows.
-
1982-1984Bio-Rad introduced HbA1c testing and the automated DIAMAT system, creating a long-lived diabetes and hemoglobin-testing franchise.
-
1999The Pasteur Sanofi Diagnostics acquisition expanded infectious-disease, microbiology, and autoimmunity capabilities, while entry into PCR broadened molecular biology exposure.
-
2011The QuantaLife acquisition added droplet digital PCR, a high-precision quantification platform that became one of Bio-Rad’s most strategically important growth technologies.
-
2017RainDance added droplet-based intellectual property and products, reinforcing the digital-PCR platform and its application breadth.
-
2025Bio-Rad acquired Stilla Technologies and launched four additional ddPCR platforms, expanding throughput, automation, multiplexing, and the range of research and diagnostic workflows.
These milestones are documented on Bio-Rad’s official history timeline. The 2025 Stilla transaction is especially important because it expands the digital-PCR portfolio from Bio-Rad’s QX200 and QX600 systems into QX Continuum and QX700 platforms. Bio-Rad stated that the combined portfolio included more than 400,000 assays and targeted applications such as oncology, infectious disease, genetic research, cell and gene therapy, organ transplantation, and food and environmental testing.
What gives Bio-Rad a competitive advantage?
Bio-Rad does not dominate every laboratory category. Its advantage is a collection of defensible specialist positions, supported by technical expertise, trusted performance, global service, installed workflows, and a portfolio that spans research through clinical use. In some categories, competitors are much larger. The strategic question is whether Bio-Rad can remain essential in selected workflows rather than outspend every rival across the entire life-science tools market.
Who are Bio-Rad’s main competitors?
| Competitive arena | Named competitors in Bio-Rad filings | Bio-Rad’s differentiating emphasis |
|---|---|---|
| Life-science research tools | Danaher, Thermo Fisher Scientific, Qiagen, Merck KGaA, Becton Dickinson | Specialized applications, technical support, comprehensive workflows, and ddPCR leadership. |
| Clinical diagnostics | Abbott, Roche, Siemens Healthineers, Danaher, bioMérieux, DiaSorin, Werfen, QuidelOrtho, Tosoh | Quality controls, blood typing, hemoglobin testing, specialty diagnostics, and workflow reliability. |
| Customer procurement | Large diversified vendors and specialized niche suppliers | Performance specifications and service can offset smaller scale, but public tenders intensify price pressure. |
How durable is the moat?
The scorecard is an analytical synthesis, not a company rating. Bio-Rad’s moat is strongest where replacing a platform risks disrupting a validated workflow. It is weaker where customers can compare standardized instruments on price or where large rivals bundle multiple laboratory categories. In a Five Forces interpretation, buyer power is meaningful because many customers are governments, hospitals, universities, and large biopharma organizations; supplier power matters for specialized components; rivalry is intense; but regulatory validation, application expertise, and installed-base switching costs raise barriers to entry.
How strong are Bio-Rad’s cash flow and balance sheet?
Bio-Rad’s financial position is unusual because the balance sheet contains both a conventional operating company and a very large publicly traded equity investment. At March 31, 2026, cash and short-term investments totaled about $1.56 billion, while the fair value of Sartorius-related equity securities was approximately $4.98 billion. Total assets were $9.79 billion and stockholders’ equity was $6.85 billion. This provides substantial financial flexibility, but it also makes book value and net income sensitive to Sartorius’s market price.
What does cash conversion look like?
The simple free-cash-flow calculation shows that the operating business remained cash generative in Q1 2026 despite the GAAP net loss. For FY2025, operating cash flow was $532.2 million, up from $455.2 million in FY2024, primarily because of improved working capital. FY2025 capital expenditures were about $157.5 million, implying approximate free cash flow of $374.7 million before acquisitions and securities transactions.
| Balance-sheet item | March 31, 2026 | Why it matters |
|---|---|---|
| Cash and cash equivalents | $507.2M | Immediate liquidity for operations, debt maturity, repurchases, and acquisitions. |
| Short-term investments | $1,057.5M | Raises total liquid resources to about $1.56B. |
| Current debt maturities | $400.5M | Primarily the 3.3% senior notes due March 2027. |
| Long-term debt | $802.9M | Primarily the 3.7% senior notes due 2032. |
| Other investments | $5,311.8M | Dominated by the Sartorius position and therefore exposed to market volatility. |
| Revolving credit facility | $200.0M capacity | No borrowings at March 31, 2026; $6.0M was used for standby letters of credit. |
How has the revenue base changed?
Capital allocation has favored repurchases and selective acquisitions rather than dividends. Bio-Rad repurchased $295.5 million of Class A shares in FY2025 and another $47.8 million in Q1 2026. At December 31, 2025, $284.6 million remained authorized under the 2023 repurchase program. The balance sheet can support these actions, but the 2027 debt maturity and the uncertain monetization of the Sartorius position should remain separate from routine operating liquidity analysis.
Who owns Bio-Rad stock, and who controls the votes?
Bio-Rad has a dual-class capital structure. Class A shares receive one-tenth of a vote per share when the two classes vote together, while Class B shares receive one vote per share. At the February 23, 2026 proxy record date, 21.9 million Class A shares and 5.1 million Class B shares were outstanding. This means economic ownership and voting influence are not proportional.
| Holder or group | Class A stake | Class B stake | Voting power | Governance implication |
|---|---|---|---|---|
| Blue Raven Partners, L.P. | 0.0% | 80.1% | 55.9% | The Schwartz family partnership alone holds majority voting power. |
| Norman Schwartz | 14.7% | 97.3% | 72.3% | Chairman and CEO has decisive influence over board elections and strategic direction. |
| First Eagle Investment Management | 11.5% | 0.0% | 3.5% | Large economic holder, but limited voting power relative to Class B owners. |
| Vanguard | 8.7% | 0.0% | 2.6% | Passive ownership does not translate into proportionate voting influence. |
| BlackRock | 7.4% | 0.0% | 2.2% | Another major Class A holder with comparatively low voting power. |
Why does controlled-company status matter?
Because the Schwartz family holds more than 50% of voting power and can elect a majority of directors through Class B ownership, Bio-Rad qualifies as a controlled company under NYSE standards. The board had four directors identified as independent in the 2026 proxy statement, and Gregory Hinckley served as lead independent director. However, Bio-Rad did not maintain a nominating committee because of the controlled-company exemption.
This structure can support long-term investment and resistance to short-term pressure, but minority shareholders have limited ability to force changes in leadership, capital allocation, board composition, or the dual-class structure. Executive incentives partly counterbalance that control: Bio-Rad’s 2025 annual bonus plan weighted global sales at 60% and operating income at 40%, explicitly linking pay to growth and profitability. Still, governance analysis should begin with voting control, not merely the percentage of Class A shares held by institutions.
What opportunities and risks could change Bio-Rad’s outlook?
The opportunity set is credible but execution-sensitive. Digital PCR can expand into oncology, liquid biopsy, cell and gene therapy, infectious disease, transplant testing, biopharma quality control, and food or environmental applications. Clinical quality controls and blood typing benefit from the recurring need for reliable laboratory results. Cost actions and manufacturing improvements could lift margins if revenue stabilizes. Yet the latest outlook reduction shows that macro, funding, and geopolitical factors can delay growth even when long-term applications remain attractive.
Which operating risks are most material?
| Risk or opportunity | Evidence | Financial line to monitor |
|---|---|---|
| Academic and biotech funding | Life Science currency-neutral sales fell 4.3% in Q1 2026. | Life Science revenue, instrument placements, and gross-margin absorption. |
| Geopolitical disruption | Middle East conflict pressured Clinical Diagnostics demand and logistics in Q1 2026. | EMEA revenue, freight costs, inventory, and order timing. |
| China reimbursement | Lower reimbursement for diabetes testing partly offset FY2025 diagnostics growth. | Asia sales, pricing, and Clinical Diagnostics gross margin. |
| Acquisition execution | FY2025 included $81.7M Dropworks and $127.7M Curiosity IPR&D impairments. | R&D productivity, impairment charges, and acquired-product revenue. |
| Sartorius volatility | A $727.7M Q1 2026 holding loss drove the reported net loss. | GAAP net income, equity, taxes, and sum-of-the-parts valuation. |
| Digital PCR expansion | Stilla and four new platforms broaden automation, multiplexing, and throughput. | Life Science organic growth, recurring consumables, and return on acquisition investment. |
One risk deserves special attention: development discipline. In 2025, Bio-Rad fully impaired the $81.7 million Dropworks in-process R&D asset after delays and lower revenue expectations, and discontinued Curiosity Diagnostics development, producing a $127.7 million impairment before related currency effects. These charges do not erase the value of Bio-Rad’s broader portfolio, but they show that acquiring promising technology does not guarantee commercialization. Future growth depends on product launch quality, adoption, manufacturing scale, and consumable pull-through.
Which KPIs matter most in a Bio-Rad valuation?
A conventional price-to-earnings ratio can mislead because Sartorius mark-to-market gains and losses create large swings in GAAP earnings. A stronger valuation approach separates the operating business from investments and then focuses on sustainable revenue growth, segment margins, free cash flow, reinvestment, and capital allocation. The operating company should be valued on normalized cash flows; the Sartorius stake and related tax effects should be analyzed separately in a sum-of-the-parts framework.
| KPI | Current reference point | Valuation relevance |
|---|---|---|
| Currency-neutral revenue growth | Q1 2026: -4.2% | Removes foreign-exchange translation and reveals underlying demand. |
| Clinical Diagnostics mix | 61.4% of Q1 2026 sales | Higher diagnostics mix can support recurring consumable revenue and stability. |
| Gross margin | Q1 2026: 52.3% | Shows pricing, product mix, manufacturing absorption, and input-cost pressure. |
| Operating margin | Q1 2026: about 5.8% GAAP | Captures the gap between strong gross margin and heavy SG&A plus R&D spending. |
| R&D intensity | Q1 2026: 10.6% of sales | Indicates how much revenue is reinvested in future platforms and assays. |
| Free cash flow | Q1 2026: about $78.1M | Measures cash available after routine capital spending. |
| Inventory | $770.5M at March 31, 2026 | High inventory can support service levels but creates working-capital and obsolescence risk. |
| Sartorius fair value | $4.98B at March 31, 2026 | Material to enterprise value, reported earnings, taxes, and balance-sheet volatility. |
What should researchers monitor next?
In a discounted cash flow model, the most sensitive assumptions are likely normalized organic growth, operating-margin recovery, working-capital efficiency, and the reinvestment needed to sustain the product pipeline. Terminal value should reflect intense competition, government-funded customers, regulated markets, and exposure to foreign exchange. The Sartorius stake should not be allowed to obscure the operating company’s normalized economics.
What is the key takeaway from Bio-Rad analysis?
Bio-Rad is a specialized life-science tools and clinical-diagnostics company with valuable installed workflows, recurring consumables, respected quality-control positions, and a long history of technical innovation. Clinical Diagnostics supplies the larger and more recurring revenue base, while Life Science provides exposure to digital PCR, bioprocessing, and advanced research applications. The company’s balance sheet is liquid and operating cash flow is positive, but headline earnings and equity are unusually volatile because of the multi-billion-dollar Sartorius investment.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.